RAD December 2023 Abstracts and Posters
All accepted abstracts will be published in The British Journal of Dermatology.503 - Visualizing 3-year treatment outcome trajectories of dupilumab in adults with moderate-to-severe atopic dermatitis in real world practice
Zhixiao Wang, Bruno Martins, Marius Ardeleanu, Min Yang, Gaëlle Bégo-Le-Bagousse, Debra Sierka, Bruce Strober
504 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis
Christopher G. Bunick, Neal Bhatia, James Del Rosso, Zoe D. Draelos, Lawrence F. Eichenfield, Leon H. Kircik, Mark G. Lebwohl, Melinda Gooderham, Lawrence J. Green, Adelaide A. Hebert, Ronald B. Vender, Matthew Zirwas, Eric L. Simpson, Linda Stein Gold, Melissa Seal, Scott Snyder, David W. Osborne, Patrick Burnett, Robert C. Higham, David H. Chu, David R. Berk
505 - Once-daily roflumilast cream 0.15% for atopic dermatitis: pooled results from INTEGUMENT-1/2 phase 3 trials
Lawrence F. Eichenfield,MD; Mark Boguniewicz, MD; Eric L. Simpson, MD; Andrew Blauvelt, MD, MBA; Melinda Gooderham, MD; Edward Lain, MD; David H. Chu, MD, PhD; Robert C. Higham, MPAS
506 - Dupilumab Is Efficacious in Patients With Prurigo Nodularis Regardless of History of Atopic Comorbidities: Pooled Results From Two Phase 3 Trials (LIBERTY-PN PRIME and PRIME2)
Brian S. Kim, Margarida Gonçalo, Tsukasa Ugajin, Amy Praestgaard, Melanie Makhija, Joseph Zahn, Ashish Bansal, Simmi Wiggins
507 - Dupilumab demonstrates greater improvement in disease activity than standard-of-care H1-antihistamines in CSU
Lisa A. Beck, Thomas B. Casale, Eric Mortensen, Elizabeth Laws, Ryan B. Thomas, Chien-Chia Chuang
508 - Dupilumab Treatment Normalizes Intraepidermal Nerve Fiber Density in Patients with Moderate-to-Severe AD
Sonja Ständer, Konstantin Agelopoulos, Leigh Nattkemper, Jerry Bagel, Amy Praestgaard, Gabriel Bologna, Madison Mack, Joseph Zahn, Annie Zhang, Gil Yosipovitch
509 - Dupilumab improves disease severity in children less than 12 years of age with moderate-severe AD: interim results from PEDISTAD Real-World Registry
Eulalia Baselga, Michele Ramien, Danielle Marcoux, Marlies de Graaf, Alan D. Irvine, Vania Oliveira Carvalho, Ledit R.F. Ardusso, Mirna Toledo-Bahena, Rajan Gupta, Thu Tong, Annie Zhang
510 - Dupilumab is Efficacious in Patients with Prurigo Nodularis Regardless of Stable Use of Topical Corticosteroids and Topical Calcineurin Inhibitors: Pooled Results from Two Phase 3 Trials (LIBERTY-PN PRIME and PRIME2)
Brian S. Kim, Gil Yosipovitch, Shawn G. Kwatra, Sonja Ständer, Nicholas Mollanazar, Genming Shi, Ashish Bansal, Melanie Makhija
512 - Dupilumab Treatment Improves Satisfaction in Patients With Prurigo Nodularis Who Did Not Achieve the Multicomponent Endpoint: Analysis From LIBERTY-PN PRIME and PRIME2
Shawn G. Kwatra, Gil Yosipovitch, Sonja Ständer, Pedro Mendes-Bastos, Tsen-Fang Tsai, Brian S. Kim, Amy Praestgaard, Ashish Bansal, Melanie Makhija, Donia Bahloul, Ryan B. Thomas, Joseph Zahn, Simmi Wiggins
513 - Blockage of IL-25 pathway as a potential target therapy for atopic dermatitis
Thomas Chin Wai HUI, Lik Hang LAM, Weimin LI, Kai Cheung CHOW, Shui On LEUNG